I was thinking along the same lines SF....

If the rates of MACE were the same in the different arms....the safety committee would be aware of that and they could reccomend a halt I believ, I've seen that before with other ph III trials.

As far as a heart attack or other event...from my understanding of the patient population undergoing this trial...its my understanding that a MAC event is almost a question of when, not if.

Its that understanding that led me to believe "no news is good news" because eventually this patient population is going to suffer a MAC event.....and hopefully (for obvious reasons) there won't be any in the apelbetalone arms, and if there are some hopefully they happen well after what would be expected...